Verona Pharma PLC
VRNA106.910USD
0.0000.00%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
73.55B시가총액
손실P/E TTM
자세한 내용은 Verona Pharma PLC 회사
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Verona Pharma PLC 정보
종목 코드 VRNA
회사 이름Verona Pharma PLC
상장일Mar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
직원 수209
유형Depository Receipt
회계 연도 종료Mar 30
주소Riverside
도시LONDON
증권 거래소NASDAQ Global Market Consolidated
국가United Kingdom
우편 번호SE1 2RE
전화442032834200
웹사이트https://www.veronapharma.com/
종목 코드 VRNA
상장일Mar 30, 2005
CEODr. David S. Zaccardelli, Pharm.D.
Verona Pharma PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Mon, Nov 17
마지막 업데이트: Mon, Nov 17
주주
주주 유형
주주
주주
비율
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
기타
77.14%
주주
주주
비율
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
기타
77.14%
주주 유형
주주
비율
Hedge Fund
41.60%
Investment Advisor/Hedge Fund
18.51%
Investment Advisor
11.73%
Research Firm
7.21%
Individual Investor
5.62%
Venture Capital
4.92%
Private Equity
4.03%
Family Office
1.16%
Pension Fund
0.30%
기타
4.92%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
467
76.61M
88.88%
-7.12M
2025Q2
423
82.86M
96.18%
-3.71M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Pentwater Capital Management LP
--
0%
+5.30M
-100.00%
HBK Investments, L.P.
--
0%
+4.26M
-100.00%
Fidelity Investments Canada ULC
--
0%
+3.49M
-100.00%
Frazier Life Sciences Management, L.P.
--
0%
--
--
Davidson Kempner Capital Management LP
--
0%
+3.27M
-100.00%
Glazer Capital, LLC
--
0%
+3.21M
-100.00%
Ali (Behbahani)
--
0%
+3.19M
-100.00%
BlackRock Financial Management, Inc.
--
0%
+2.83M
-100.00%
New Enterprise Associates (NEA)
--
0%
-10.14K
-100.00%
Goldman Sachs & Company, Inc.
--
0%
-685.23K
-100.00%
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
iShares Disciplined Volatility Equity Active ETF
0%
AltShares Merger Arbitrage ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Rayliant Quantitative Developed Market Equity ETF
0%
Calvert International Responsible Index ETF
0%
iShares Biotechnology ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
JPMorgan Healthcare Leaders ETF
0%
Global X Guru Index ETF
0%
더 보기
iShares Disciplined Volatility Equity Active ETF
비율0%
AltShares Merger Arbitrage ETF
비율0%
SPDR Portfolio Developed World ex-US ETF
비율0%
Rayliant Quantitative Developed Market Equity ETF
비율0%
Calvert International Responsible Index ETF
비율0%
iShares Biotechnology ETF
비율0%
Fidelity Nasdaq Composite Index ETF
비율0%
First Trust IPOX Europe Equity Opportunities ETF
비율0%
JPMorgan Healthcare Leaders ETF
비율0%
Global X Guru Index ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
